Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Aurixim by BioIntegrator for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Aurixim is under clinical development by BioIntegrator and currently in Phase I for Nodal Marginal Zone B-Cell Lymphoma. According to...
Aurixim by BioIntegrator for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Aurixim is under clinical development by BioIntegrator and currently in Phase I for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
Aurixim by BioIntegrator for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Aurixim is under clinical development by BioIntegrator and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Aurixim by BioIntegrator for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Aurixim is under clinical development by BioIntegrator and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Aurixim by BioIntegrator for Follicular Lymphoma: Likelihood of Approval
Aurixim is under clinical development by BioIntegrator and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I...
Aurixim by BioIntegrator for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Aurixim is under clinical development by BioIntegrator and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData,...